首页 > 市场调查报告书 > 製药

医药品原料药

市场调查报告书

商品编码

1392257

全球微生物 API 市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势和预测

Global Microbial API Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年11月01日 | 出版商:

Value Market Research | 英文 335 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2030 年，全球微生物 API 市场需求将从 2022 年的 602.1 亿美元达到近 1,050.9 亿美元的市场规模，2023-2030 年研究期间CAGR为 7.21%。

微生物API是指源自微生物的活性药物成分，例如细菌、真菌或其他微生物。这些原料药是药物中的核心治疗成分，对身体有药理作用。

市场动态：

微生物 API 市场的成长是由多个相互关联的因素所推动的。由于感染和抗生素抗药性的增加，对抗生素的需求增加，推动了对微生物源 API 的需求。技术进步，特别是生物技术和基因工程的进步，彻底改变了微生物发酵，使其生产复杂 API 的效率更高且更具成本效益。製药业的扩张和对创新药物的追求极大地增加了对多种微生物 API 的需求，特别是随着对生物製药的关注不断加强。支持药物安全性和有效性的政府法规，以及促进新药开发的倡议，对这个市场产生了正面影响。製药公司和研究机构之间的合作，加上对研发的大量投资，加速了微生物 API 的发现和生产。在医疗保健支出和意识增加的推动下，新兴经济体市场的扩张进一步刺激了对负担得起的药物的需求。此外，微生物原料药生产方法的环境永续性使其相对于传统化学合成更受青睐，为微生物製药製造带来了光明的未来。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球微生物原料药市场的各个细分市场进行了包容性评估。微生物原料药产业的成长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲微生物 API 市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。微生物原料药市场的主要参与者包括默克公司、天方药业有限公司、帝斯曼、石药集团有限公司、可隆生命科学、山东鲁抗製药有限公司、梯瓦製药工业有限公司。，龙沙。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
产业动态
波特五力分析
市场吸引力分析
- 主办单位市场吸引力分析
- 按类型分類的市场吸引力分析
- 按网站分類的市场吸引力分析
- 按最终用途分類的市场吸引力分析
- 分子市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
潜在买家名单
行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势

第 5 章：全球微生物 API 市场分析：依主机分类

主持人概述
历史和预测数据
主持人分析
哺乳动物
细菌
真菌

第 6 章：全球微生物 API 市场分析：按类型

按类型概述
历史和预测数据
按类型分析
抗体
胜肽
蛋白质
小分子
疫苗

第 7 章：全球微生物 API 市场分析：按地点

按站点概述
历史和预测数据
按站点分析
内部
外包

第 8 章：全球微生物 API 市场分析：依最终用途分类

按最终用途分類的概述
历史和预测数据
按最终用途分析
製药公司
生物製药公司
其他的

第 9 章：全球微生物 API 市场分析：按分子

分子概述
历史和预测数据
分子分析
创新的
通用的

第 10 章：全球微生物 API 市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 11 章：微生物 API 公司的竞争格局

微生物原料药市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 12 章：公司简介

公司股份分析
市场集中度
Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Topfond Pharmaceutical Co. Ltd.

公司简介
公司收入
产品
最近的发展

公司简介
公司收入
产品
最近的发展

CSPC Pharmaceutical Group Limited

公司简介
公司收入
产品
最近的发展

KOLON LIFE SCIENCE

公司简介
公司收入
产品
最近的发展

Shandong Lukang Pharmaceutical Co. Ltd.

公司简介
公司收入
产品
最近的发展

Teva Pharmaceutical Industries Ltd.

公司简介
公司收入
产品
最近的发展

Lonza

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112112866

The global demand for Microbial API Market is presumed to reach the market size of nearly USD 105.09 BN by 2030 from USD 60.21 BN in 2022 with a CAGR of 7.21% under the study period 2023 - 2030.

Microbial API refers to Active Pharmaceutical Ingredients derived from microorganisms, such as bacteria, fungi, or other microorganisms. These APIs are the core therapeutic components in medications that exert a pharmacological effect on the body.

MARKET DYNAMICS:

The microbial API market's growth is driven by multiple interconnected factors. Heightened demand for antibiotics due to increasing infections and antibiotic resistance propels the need for microbial-derived APIs. Technological advancements, particularly in biotechnology and genetic engineering, have revolutionized microbial fermentation, making it more efficient and cost-effective for producing complex APIs. The pharmaceutical industry's expansion and pursuit of innovative drugs contribute significantly to the demand for diverse microbial APIs, especially as the focus on biopharmaceuticals intensifies. Government regulations supporting drug safety and efficacy, alongside initiatives promoting new drug development, positively influence this market. Collaborations between pharmaceutical firms and research institutions, coupled with substantial investments in R&D, accelerate microbial API discovery and production. The market's expansion in emerging economies, driven by increased healthcare spending and awareness, further fuels the demand for affordable medications. Additionally, the environmental sustainability of microbial API production methods has led to their preference over traditional chemical synthesis, fostering a promising future for microorganism-based pharmaceutical manufacturing.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of microbial api. The growth and trends of microbial api industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the microbial api market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Host

Mammalian
Bacterial
Fungal

By Type

Antibody
Peptide
Protein
Small Molecule
Vaccine

By Site

In-House
Outsourced

By End-Use

Pharmaceutical Companies
Biopharmaceutical Companies
Others

By Molecule

Innovative
Generic

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Microbial API market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Microbial API market include Merck & Co., Inc., Topfond Pharmaceutical Co., Ltd., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Lonza. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . MICROBIAL API - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Host
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Site
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Molecule
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MICROBIAL API MARKET ANALYSIS BY HOST

5.1 Overview by Host
5.2 Historical and Forecast Data
5.3 Analysis by Host
5.4 Mammalian Historic and Forecast Sales by Regions
5.5 Bacterial Historic and Forecast Sales by Regions
5.6 Fungal Historic and Forecast Sales by Regions

6 . GLOBAL MICROBIAL API MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Antibody Historic and Forecast Sales by Regions
6.5 Peptide Historic and Forecast Sales by Regions
6.6 Protein Historic and Forecast Sales by Regions
6.7 Small Molecule Historic and Forecast Sales by Regions
6.8 Vaccine Historic and Forecast Sales by Regions

7 . GLOBAL MICROBIAL API MARKET ANALYSIS BY SITE

7.1 Overview by Site
7.2 Historical and Forecast Data
7.3 Analysis by Site
7.4 In-house Historic and Forecast Sales by Regions
7.5 Outsourced Historic and Forecast Sales by Regions

8 . GLOBAL MICROBIAL API MARKET ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Pharmaceutical Companies Historic and Forecast Sales by Regions
8.5 Biopharmaceutical Companies Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL MICROBIAL API MARKET ANALYSIS BY MOLECULE

9.1 Overview by Molecule
9.2 Historical and Forecast Data
9.3 Analysis by Molecule
9.4 Innovative Historic and Forecast Sales by Regions
9.5 Generic Historic and Forecast Sales by Regions

10 . GLOBAL MICROBIAL API MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Data Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Data Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Data Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. South East Asia Sales Analysis
- 10.5.10. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Data Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Data Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE MICROBIAL API COMPANIES

11.1. Microbial Api Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF MICROBIAL API INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. Merck & Co. Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Topfond Pharmaceutical Co. Ltd.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. DSM
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. CSPC Pharmaceutical Group Limited
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. KOLON LIFE SCIENCE
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Shandong Lukang Pharmaceutical Co. Ltd.
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Teva Pharmaceutical Industries Ltd.
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Lonza
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments